



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

October 2019





© 2019 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS
Drug Treatment Program**

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

October 2019

N = 7410



Health Authority	Male	Female	All
FRASER	1439	430	1869
INTERIOR	414	96	510
NORTHERN	132	87	219
VANCOUVER COASTAL	3399	442	3841
VANCOUVER ISLAND	777	155	932
	6161	1210	7371
		Unknown/not stated:	39
		Total:	7410

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (October 2014 - October 2019)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (October 2014 - October 2019)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (October 2014 - October 2019)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (October 2014 - October 2019)






1.6 Percent Distribution of Active Participants by CD4 Count (October 2014 - October 2019)






1.7 Percent Distribution of Inactive Participants by CD4 Count (October 2014 - October 2019)






1.8 Active and Inactive Participants (October 2014 - October 2019)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (October 2014 - October 2019)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (October 2014 - October 2019)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(October 2014 - October 2019)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (October 2014 - October 2019)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(October 2014 - October 2019)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (October 2014 - October 2019)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(October 2014 - October 2019)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (October 2014 - October 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(October 2014 - October 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts (October 2014 - October 2019)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(October 2014 - October 2019)**






1.20 Cumulative Resistance Testing Results by Resistance Category (October 2014 - October 2019)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (October 2014 - October 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	2	575	5	<40	3
1988	28	6	0	6	5	420	6	<40	3
1989	26	52	1	53	42	555	53	<40	3
1990	25	54	1	55	36	460	54	<40	3
1991	25	36	3	39	25	590	39	<40	3
1992	25	63	5	68	42	515	64	<40	3
1993	24	132	14	146	125	540	142	<40	3
1994	23	79	12	91	69	520	87	<40	3
1995	23	131	21	152	122	550	147	<40	3
1996	21	347	53	400	303	564	385	<40	3
1997	19	277	32	309	242	630	289	<40	3
1998	18	194	41	235	177	560	220	<40	3
1999	18	157	38	195	150	580	187	<40	3
2000	18	124	33	157	126	580	150	<40	3
2001	18	122	29	151	115	590	146	<40	3
2002	17	121	26	147	115	590	137	<40	3
2003	16	154	30	184	137	590	181	<40	3
2004	15	157	40	197	159	580	190	<40	3
2005	14	188	46	234	190	650	223	<40	3
2006	13	185	40	225	185	610	217	<40	3
2007	12	253	49	302	241	640	281	<40	3
2008	11	283	65	348	277	650	327	<40	3
2009	10	310	69	379	300	646	359	<40	3
2010	9	279	72	351	281	630	327	<40	3
2011	8	332	74	406	316	670	377	<40	3
2012	7	271	63	334	261	700	308	<40	3
2013	6	273	67	340	255	650	312	<40	3
2014	5	287	56	343	255	700	317	<40	3
2015	4	292	50	342	259	690	316	<40	3
2016	3	282	57	339	257	656	321	<40	3
2017	2	237	35	272	222	630	258	<40	3
2018	1	219	51	270	227	640	263	<40	3
2019	1	224	42	266	224	610	258	<40	3
Total:		6126	1215	7341					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7281	750	2385	<40	2109	610
FEB-2018	7245	763	1904	<40	1744	610
MAR-2018	7270	769	2050	<40	1831	617
APR-2018	7256	776	2080	<40	1841	620
MAY-2018	7273	773	2147	<40	1928	600
JUN-2018	7273	787	2002	<40	1786	610
JUL-2018	7283	785	2037	<40	1810	600
AUG-2018	7288	795	2092	<40	1874	620
SEP-2018	7244	794	2015	<40	1787	620
OCT-2018	7338	773	2170	<40	1945	610
NOV-2018	7341	780	2091	<40	1814	630
DEC-2018	7358	787	1747	<40	1536	620
JAN-2019	7398	792	2456	<40	2142	610
FEB-2019	7379	799	1854	<40	1581	620
MAR-2019	7417	790	2086	<40	1753	610
APR-2019	7374	793	2143	<40	1744	610
MAY-2019	7433	792	2127	<40	1756	620
JUN-2019	7383	803	1928	<40	1578	616
JUL-2019	7391	808	2112	<40	1671	620
AUG-2019	7380	810	2109	<40	1576	610
SEP-2019	7359	809	2015	<40	1494	600
OCT-2019	7410	789	2141	<40	1620	630

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1428	3315	79	890	71	380
FEB-2018	1472	3112	79	1036	66	440
MAR-2018	1456	3198	75	59	70	485
APR-2018	1474	3163	73	459	63	497
MAY-2018	1463	3228	93	<40	82	455
JUN-2018	1473	3226	74	1260	70	440
JUL-2018	1473	3257	70	<40	55	570
AUG-2018	1502	3163	64	63	60	485
SEP-2018	1546	2985	88	220	82	410
OCT-2018	1473	3335	79	<50	69	350
NOV-2018	1485	3311	82	87	74	480
DEC-2018	1481	3343	57	355	47	490
JAN-2019	1470	3415	73	73	65	350
FEB-2019	1500	3324	75	108	66	590
MAR-2019	1465	3496	74	885	61	400
APR-2019	1501	3381	80	<50	70	490
MAY-2019	1448	3609	78	87	67	460
JUN-2019	1503	3422	77	<40	68	535
JUL-2019	1493	3487	70	<40	57	540
AUG-2019	1515	3441	78	50	64	505
SEP-2019	1547	3292	93	<40	72	575
OCT-2019	1492	3589	80	120	64	485

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7242	1428	12	12	193	127	56	13218
FEB-2018	7211	1472	11	27	125	169	-31	13255
MAR-2018	7231	1456	17	21	158	138	20	13282
APR-2018	7223	1474	12	15	154	161	-8	13304
MAY-2018	7243	1463	9	12	173	153	20	13329
JUN-2018	7239	1473	13	16	152	156	-4	13351
JUL-2018	7241	1473	13	13	165	155	2	13377
AUG-2018	7252	1502	9	27	158	159	11	13416
SEP-2018	7207	1546	14	15	155	194	-45	13442
OCT-2018	7306	1473	8	19	218	126	99	13478
NOV-2018	7314	1485	5	9	171	164	8	13504
DEC-2018	7330	1481	11	19	152	142	16	13529
JAN-2019	7365	1470	14	20	191	159	35	13564
FEB-2019	7351	1500	7	16	160	180	-14	13593
MAR-2019	7376	1465	15	13	187	147	25	13613
APR-2019	7332	1501	10	15	151	179	-44	13641
MAY-2019	7395	1448	11	21	197	138	63	13683
JUN-2019	7343	1503	14	13	137	184	-52	13704
JUL-2019	7355	1493	13	13	178	163	12	13727
AUG-2019	7352	1515	12	18	167	174	-3	13763
SEP-2019	7329	1547	13	16	180	202	-23	13791
OCT-2019	7341	1492	3	12	221	152	12	13819

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	60	6718	448	55	7281	0.82%	92.27%	6.15%	0.76%	100.00%
FEB-2018	64	6672	450	59	7245	0.88%	92.09%	6.21%	0.81%	100.00%
MAR-2018	62	6699	453	56	7270	0.85%	92.15%	6.23%	0.77%	100.00%
APR-2018	62	6688	449	57	7256	0.85%	92.17%	6.19%	0.79%	100.00%
MAY-2018	69	6691	455	58	7273	0.95%	92.00%	6.26%	0.80%	100.00%
JUN-2018	62	6707	447	57	7273	0.85%	92.22%	6.15%	0.78%	100.00%
JUL-2018	53	6717	458	55	7283	0.73%	92.23%	6.29%	0.76%	100.00%
AUG-2018	56	6722	454	56	7288	0.77%	92.23%	6.23%	0.77%	100.00%
SEP-2018	55	6676	456	57	7244	0.76%	92.16%	6.29%	0.79%	100.00%
OCT-2018	54	6756	474	54	7338	0.74%	92.07%	6.46%	0.74%	100.00%
NOV-2018	53	6763	475	50	7341	0.72%	92.13%	6.47%	0.68%	100.00%
DEC-2018	52	6780	477	49	7358	0.71%	92.14%	6.48%	0.67%	100.00%
JAN-2019	54	6805	486	53	7398	0.73%	91.98%	6.57%	0.72%	100.00%
FEB-2019	52	6786	492	49	7379	0.70%	91.96%	6.67%	0.66%	100.00%
MAR-2019	59	6818	490	50	7417	0.80%	91.92%	6.61%	0.67%	100.00%
APR-2019	56	6780	490	48	7374	0.76%	91.94%	6.64%	0.65%	100.00%
MAY-2019	55	6841	492	45	7433	0.74%	92.04%	6.62%	0.61%	100.00%
JUN-2019	58	6796	481	48	7383	0.79%	92.05%	6.51%	0.65%	100.00%
JUL-2019	59	6792	492	48	7391	0.80%	91.90%	6.66%	0.65%	100.00%
AUG-2019	58	6787	485	50	7380	0.79%	91.96%	6.57%	0.68%	100.00%
SEP-2019	56	6764	486	53	7359	0.76%	91.91%	6.60%	0.72%	100.00%
OCT-2019	61	6808	487	54	7410	0.82%	91.88%	6.57%	0.73%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	10 36%	3314 47%	9 32%	3070 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3628 51%
FEB-2018	13 35%	3315 47%	12 32%	3073 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3578 51%
MAR-2018	10 37%	3334 47%	10 37%	3099 44%	0 0%	59 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3563 50%
APR-2018	5 23%	3342 47%	5 23%	3111 44%	0 0%	55 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3533 50%
MAY-2018	9 39%	3350 48%	8 35%	3124 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3504 50%
JUN-2018	7 35%	3364 48%	7 35%	3141 45%	0 0%	53 1%	0 0%	5 0%	0 0%	3 0%	1 5%	379 5%	12 60%	3473 49%
JUL-2018	7 28%	3393 48%	7 28%	3171 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3444 49%
AUG-2018	13 33%	3392 48%	14 36%	3180 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3413 48%
SEP-2018	4 15%	3377 48%	3 12%	3162 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3364 48%
OCT-2018	11 31%	3418 48%	9 26%	3205 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	479 7%	25 71%	3382 47%
NOV-2018	9 35%	3428 48%	8 31%	3214 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	491 7%	17 65%	3351 47%
DEC-2018	8 32%	3446 48%	8 32%	3233 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	504 7%	15 60%	3348 47%
JAN-2019	8 23%	3471 48%	7 20%	3258 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3360 47%
FEB-2019	13 45%	3464 48%	12 41%	3263 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	542 8%	13 45%	3310 46%
MAR-2019	6 30%	3477 48%	6 30%	3280 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3310 46%
APR-2019	12 43%	3478 48%	12 43%	3286 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3253 45%
MAY-2019	14 34%	3510 49%	14 34%	3318 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	23 56%	3265 45%
JUN-2019	3 14%	3491 49%	3 14%	3303 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	610 8%	16 76%	3209 45%
JUL-2019	8 35%	3514 49%	8 35%	3333 46%	0 0%	39 1%	0 0%	2 0%	0 0%	1 0%	1 4%	626 9%	14 61%	3190 44%
AUG-2019	14 39%	3519 49%	12 33%	3344 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	632 9%	20 56%	3155 44%
SEP-2019	6 21%	3499 49%	6 21%	3323 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 18%	657 9%	17 61%	3135 44%
OCT-2019	4 15%	3519 49%	2 7%	3338 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	671 9%	22 81%	3154 44%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2018	18	64%	3704	52%
FEB-2018	24	65%	3672	52%
MAR-2018	17	63%	3669	52%
APR-2018	17	77%	3655	52%
MAY-2018	14	61%	3650	52%
JUN-2018	13	65%	3650	52%
JUL-2018	18	72%	3647	52%
AUG-2018	25	64%	3646	52%
SEP-2018	22	85%	3624	51%
OCT-2018	24	69%	3683	52%
NOV-2018	17	65%	3667	51%
DEC-2018	17	68%	3669	51%
JAN-2019	27	77%	3699	51%
FEB-2019	16	55%	3679	51%
MAR-2019	14	70%	3706	51%
APR-2019	16	57%	3669	51%
MAY-2019	27	66%	3694	51%
JUN-2019	18	86%	3656	51%
JUL-2019	15	65%	3664	51%
AUG-2019	22	61%	3639	51%
SEP-2019	22	79%	3639	51%
OCT-2019	23	85%	3678	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1313 45%	7 70%	1414 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1255 44%	15 100%	1420 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1243 43%	10 91%	1438 50%	0 0%	187 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1220 43%	11 100%	1435 50%	0 0%	180 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1204 42%	5 100%	1438 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1185 42%	11 92%	1428 51%	0 0%	175 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1168 42%	7 70%	1438 52%	1 10%	168 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1155 42%	11 69%	1422 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1132 42%	6 86%	1404 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1121 41%	15 83%	1445 53%	0 0%	153 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1456 53%	0 0%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1457 54%	1 11%	145 5%	0 0%	0 0%	0 0%	2 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1098 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1071 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1487 55%	0 0%	133 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1028 39%	7 70%	1479 56%	2 20%	133 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1034 39%	11 92%	1481 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1004 39%	9 100%	1468 57%	0 0%	120 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	984 38%	7 100%	1487 57%	0 0%	113 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	971 38%	11 92%	1463 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	956 37%	12 92%	1485 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	959 37%	13 93%	1495 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	3 50%	778 37%	1 17%	262 12%	2 33%	757 36%	0 0%	302 14%
FEB-2018	0 0%	0 0%	3 75%	769 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	0 0%	0 0%	1 33%	757 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	0 0%	0 0%	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	0 0%	0 0%	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	0 0%	0 0%	1 50%	720 36%	0 0%	248 12%	0 0%	724 36%	1 50%	313 16%
JUL-2018	0 0%	0 0%	3 60%	721 36%	0 0%	243 12%	0 0%	717 36%	2 40%	313 16%
AUG-2018	0 0%	0 0%	2 100%	714 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	0 0%	0 0%	6 100%	706 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	0 0%	0 0%	3 60%	696 36%	0 0%	234 12%	0 0%	710 36%	2 40%	323 16%
NOV-2018	0 0%	0 0%	8 80%	687 35%	0 0%	230 12%	0 0%	700 36%	2 20%	322 17%
DEC-2018	0 0%	0 0%	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	319 17%
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	646 35%	0 0%	223 12%	0 0%	678 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	5 100%	647 35%	0 0%	219 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	635 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	635 35%	0 0%	211 12%	0 0%	657 36%	0 0%	323 18%
AUG-2019	0 0%	1 0%	2 100%	626 35%	0 0%	207 11%	0 0%	647 36%	0 0%	327 18%
SEP-2019	0 0%	1 0%	4 80%	613 35%	0 0%	209 12%	0 0%	623 35%	1 20%	325 18%
OCT-2019	0 0%	1 0%	5 56%	613 35%	1 11%	211 12%	2 22%	596 34%	1 11%	330 19%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2003 60%	8 42%	630 19%	0 0%	46 1%	2 11%	685 21%
FEB-2018	0 0%	0 0%	16 70%	2023 60%	6 26%	640 19%	0 0%	45 1%	1 4%	675 20%
MAR-2018	0 0%	0 0%	14 100%	2058 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2102 61%	4 33%	653 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2135 61%	4 20%	664 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	8 73%	2167 61%	2 18%	672 19%	0 0%	42 1%	1 9%	676 19%
JUL-2018	0 0%	0 0%	7 58%	2201 62%	4 33%	674 19%	0 0%	42 1%	1 8%	675 19%
AUG-2018	0 0%	0 0%	23 79%	2251 62%	5 17%	675 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	689 19%	0 0%	41 1%	0 0%	655 18%
OCT-2018	0 0%	17 0%	13 76%	2318 63%	4 24%	708 19%	0 0%	40 1%	0 0%	658 18%
NOV-2018	0 0%	17 0%	11 100%	2344 63%	0 0%	703 19%	0 0%	38 1%	0 0%	650 17%
DEC-2018	0 0%	17 0%	13 76%	2367 63%	4 24%	719 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	730 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2436 63%	5 23%	727 19%	0 0%	40 1%	1 5%	653 17%
MAR-2019	0 0%	27 1%	8 62%	2484 64%	5 38%	747 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2501 64%	3 21%	739 19%	0 0%	36 1%	3 21%	637 16%
MAY-2019	0 0%	27 1%	19 68%	2566 64%	6 21%	748 19%	0 0%	37 1%	3 11%	636 16%
JUN-2019	0 0%	27 1%	10 77%	2567 65%	3 23%	746 19%	0 0%	37 1%	0 0%	625 16%
JUL-2019	0 0%	27 1%	14 82%	2611 65%	3 18%	758 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2651 65%	1 4%	756 19%	0 0%	36 1%	3 11%	627 15%
SEP-2019	0 0%	28 1%	8 50%	2656 65%	6 38%	759 19%	0 0%	37 1%	2 13%	629 15%
OCT-2019	0 0%	28 1%	13 87%	2726 66%	1 7%	761 18%	0 0%	34 1%	1 7%	629 15%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2004	27.52	1644	22.58	2592	35.60	117	1.61	55	0.76	869	11.94
FEB-2018	1961	27.07	1629	22.48	2610	36.02	116	1.60	59	0.81	870	12.01
MAR-2018	1974	27.15	1615	22.21	2644	36.37	113	1.55	56	0.77	868	11.94
APR-2018	1928	26.57	1596	22.00	2696	37.16	114	1.57	57	0.79	865	11.92
MAY-2018	1918	26.37	1575	21.66	2732	37.56	114	1.57	58	0.80	876	12.04
JUN-2018	1903	26.17	1562	21.48	2784	38.28	113	1.55	57	0.78	854	11.74
JUL-2018	1886	25.90	1565	21.49	2813	38.62	110	1.51	55	0.76	854	11.73
AUG-2018	1860	25.52	1549	21.25	2859	39.23	111	1.52	56	0.77	853	11.70
SEP-2018	1823	25.17	1532	21.15	2878	39.73	109	1.50	57	0.79	845	11.66
OCT-2018	1848	25.18	1529	20.84	2946	40.15	104	1.42	54	0.74	857	11.68
NOV-2018	1842	25.09	1522	20.73	2966	40.40	106	1.44	50	0.68	855	11.65
DEC-2018	1835	24.94	1510	20.52	3005	40.84	104	1.41	49	0.67	855	11.62
JAN-2019	1833	24.78	1481	20.02	3063	41.40	100	1.35	53	0.72	868	11.73
FEB-2019	1805	24.46	1479	20.04	3079	41.73	99	1.34	49	0.66	868	11.76
MAR-2019	1795	24.20	1473	19.86	3131	42.21	98	1.32	50	0.67	870	11.73
APR-2019	1762	23.89	1461	19.81	3146	42.66	100	1.36	48	0.65	857	11.62
MAY-2019	1774	23.87	1449	19.49	3210	43.19	97	1.30	45	0.61	858	11.54
JUN-2019	1746	23.65	1440	19.50	3210	43.48	95	1.29	48	0.65	844	11.43
JUL-2019	1719	23.26	1429	19.33	3246	43.92	92	1.24	48	0.65	857	11.60
AUG-2019	1691	22.91	1404	19.02	3299	44.70	94	1.27	50	0.68	842	11.41
SEP-2019	1701	23.11	1368	18.59	3305	44.91	93	1.26	53	0.72	839	11.40
OCT-2019	1708	23.05	1344	18.14	3364	45.40	93	1.26	54	0.73	847	11.43

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	13	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	19	2	0	5	5	7	380
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	21	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	16	0	0	2	4	8	535
OCT-2019	12	1	1	3	4	3	415

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11956	3652
FEB-2018	11986	3667
MAR-2018	12013	3696
APR-2018	12045	3726
MAY-2018	12080	3751
JUN-2018	12092	3754
JUL-2018	12118	3778
AUG-2018	12132	3773
SEP-2018	12155	3794
OCT-2018	12174	3794
NOV-2018	12211	3813
DEC-2018	12215	3808
JAN-2019	12255	3833
FEB-2019	12264	3833
MAR-2019	12294	3863
APR-2019	12321	3887
MAY-2019	12337	3888
JUN-2019	12337	3893
JUL-2019	12354	3908
AUG-2019	12386	3925
SEP-2019	12407	3943
OCT-2019	12450	3977

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
October 2019

N = 7410

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2019

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	10	11	*
	50+	28	40	*
	Total HSDA:	44	57	29
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	97	52	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	364	493	279	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	12
	35-49	*	*	50
	50+	*	*	88
Total HSDA:	191	259	150	
Total HA:		672	906	510

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	62	63	*
	35-49	179	199	*
	50+	426	639	*
Total HA:		672	906	510

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	538	727	414
Female	134	179	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	510	55	600	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	19	11
	5 years or more	12	7
	<5 years	13	11
	Total HSDA:	44	29
KOOTENAY BOUNDARY	10 years or more	45	33
	5 years or more	15	9
	<5 years	13	10
	Total HSDA:	73	52
OKANAGAN	10 years or more	225	164
	5 years or more	69	55
	<5 years	70	60
	Total HSDA:	364	279
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	106	79
	5 years or more	41	34
	<5 years	44	37
	Total HSDA:	191	150
Total HA:		672	510

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	395	287
	5 years or more	137	105
	<5 years	140	118
Total HA:		672	510

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	41	59	10	21
KOOTENAY BOUNDARY	71	121	21	42
OKANAGAN	214	922	54	286
THOMPSON/CARIBOO/SHUSWAP	133	507	38	133
Total:	459	1609	123	482

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	90

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	30	32	21
	35-49	105	115	78
	50+	235	309	183
	Total HSDA:		377	463
FRASER NORTH	0-19	9	9	*
	20-34	110	111	*
	35-49	349	379	*
	50+	554	878	*
	Total HSDA:		1022	1377
FRASER SOUTH	0-19	7	7	6
	20-34	121	123	90
	35-49	326	372	267
	50+	539	793	451
	Total HSDA:		993	1295
Total HA:		2392	3135	1869

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	23	23	13
	20-34	261	266	185
	35-49	780	866	604
	50+	1328	1980	1067
Total HA:		2392	3135	1869

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1816	2402	1439
Female	576	733	430

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1869	52	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	221	169
	5 years or more	74	57
	<5 years	82	62
	Total HSDA:	377	288
FRASER NORTH	10 years or more	568	402
	5 years or more	243	193
	<5 years	211	172
	Total HSDA:	1022	767
FRASER SOUTH	10 years or more	541	433
	5 years or more	228	183
	<5 years	224	198
	Total HSDA:	993	814
Total HA:		2392	1869

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1330	1004
	5 years or more	545	433
	<5 years	517	432
Total HA:		2392	1869

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	141	496	28	59
FRASER NORTH	247	1564	45	232
FRASER SOUTH	212	1460	43	453
Total:	600	3520	116	744

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	201
FRASER NORTH	640
FRASER SOUTH	497
Total:	1338

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	21
	35-49	*	*	65
	50+	*	*	205
	Total HSDA:		335	482
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		174	223
VANCOUVER	0-19	29	29	7
	20-34	441	455	314
	35-49	1376	1552	996
	50+	2817	4807	2097
	Total HSDA:	4663	6843	3414
Total HA:		5172	7548	3841

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	32	32	8
	20-34	494	509	356
	35-49	1497	1685	1093
	50+	3149	5322	2384
Total HA:		5172	7548	3841

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4568	6630	3399
Female	602	916	442

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3841	53	640	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	186	155
	5 years or more	87	80
	<5 years	62	56
	Total HSDA:	335	291
RICHMOND	10 years or more	100	73
	5 years or more	38	31
	<5 years	36	32
	Total HSDA:	174	136
VANCOUVER	10 years or more	2749	1938
	5 years or more	1149	839
	<5 years	765	637
	Total HSDA:	4663	3414
Total HA:		5172	3841

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3035	2166
	5 years or more	1274	950
	<5 years	863	725
Total HA:		5172	3841

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	168	491	51	176
RICHMOND	43	287	11	94
VANCOUVER	598	10790	198	5272
Total:	809	11568	260	5542

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	8
RICHMOND	5
VANCOUVER	96
Total:	109

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	22
	35-49	*	*	66
	50+	*	*	177
	Total HSDA:		321	455
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		124	166
SOUTH VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	52
	35-49	*	*	141
	50+	*	*	370
	Total HSDA:		736	1041
Total HA:		1181	1662	932

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	110	117	*
	35-49	304	356	*
	50+	762	1184	*
Total HA:		1181	1662	932

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	973	1368	777
Female	208	294	155

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	932	54	550	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	175	146
	5 years or more	71	58
	<5 years	75	61
	Total HSDA:	321	265
NORTH VANCOUVER ISLAND	10 years or more	72	61
	5 years or more	31	24
	<5 years	21	19
	Total HSDA:	124	104
SOUTH VANCOUVER ISLAND	10 years or more	422	302
	5 years or more	166	141
	<5 years	148	120
	Total HSDA:	736	563
Total HA:		1181	932

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	669	509
5 years or more	268	223
<5 years	244	200
Total HA:	1181	932

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	859	74	199
NORTH VANCOUVER ISLAND	138	267	48	81
SOUTH VANCOUVER ISLAND	210	1785	42	555
Total:	539	2911	164	835

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	51
NORTH VANCOUVER ISLAND	39
SOUTH VANCOUVER ISLAND	106
Total:	196

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	20-34	11	12	7
	35-49	17	32	14
	50+	41	63	33
	Total HSDA:	69	107	54
NORTHERN INTERIOR	0-19	5	5	*
	20-34	25	26	*
	35-49	72	91	*
	50+	90	151	*
	Total HSDA:	192	273	142
Total HA:		301	428	219

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	39	41	*
	35-49	109	146	*
	50+	147	235	*
Total HA:		301	428	219

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	181	263	132
Female	120	165	87

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	219	50	550	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	20	*
	5 years or more	12	*
	<5 years	8	*
	Total HSDA:	40	23
NORTH WEST	10 years or more	34	25
	5 years or more	21	18
	<5 years	14	11
	Total HSDA:	69	54
NORTHERN INTERIOR	10 years or more	76	55
	5 years or more	62	49
	<5 years	54	38
	Total HSDA:	192	142
Total HA:		301	219

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	130	91
	5 years or more	95	75
	<5 years	76	53
Total HA:		301	219

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	39	63	7	8
NORTH WEST	71	162	13	29
NORTHERN INTERIOR	105	465	15	183
Total:	215	690	35	220

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	20
NORTHERN INTERIOR	18
Total:	44

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	11	5
	KOOTENAY BOUNDARY	6	9	5
	OKANAGAN	22	38	13
	THOMPSON/CARIBOO/SHUSWAP	25	45	20
	Total HA:	60	103	43
FRASER	FRASER EAST	43	53	29
	FRASER NORTH	54	90	46
	FRASER SOUTH	71	104	54
	Total HA:	168	247	129
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	28	51	27
	RICHMOND	10	15	7
	VANCOUVER	481	852	379
	Total HA:	519	918	413
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	80	42
	NORTH VANCOUVER ISLAND	17	26	16
	SOUTH VANCOUVER ISLAND	36	79	28
	Total HA:	104	185	86
NORTHERN	NORTH EAST	10	12	8
	NORTH WEST	28	57	22
	NORTHERN INTERIOR	75	112	60
	Total HA:	113	181	90
Total:		964	1634	761

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	603	1040	476
Female	361	594	285

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	761	51	480	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

